Skip to main content
. 2021 Apr 13;15:631825. doi: 10.3389/fnins.2021.631825

FIGURE 4.

FIGURE 4

The D2R agonist quinpirole prevented methamphetamine-enhanced vesicular DA release in SELENOP1 KO NAc. (A) representative DA signal traces of quinpirole-enhanced D2R auto-inhibition of evoked DA release from C57 WT mice and C57 SELENOP1 KO mice, aged 3–5 months. (B) quinpirole (Quin; 30 nM) reduced basal DA release in WT (–54.1 ± 2.8%; n = 3) and SELENOP1 KO (–58.4 ± 3.9%; n = 3) mice similarly (p = 0.4). Measurements followed 15 min of quinpirole exposure (last stimulation prior to 10 μM methamphetamine (METH) application). Quinpirole also suppressed the methamphetamine-induced increase in [DA]r in SELENOP1 KO mice. WT and SELENOP1 KO mice had comparable responses to methamphetamine following quinpirole. (C) mean (± SEM) changes in [DA]r in response to quinpirole and methamphetamine compared to pre-quinpirole baseline levels using a two-way ANOVA. Quinpirole reduced the methamphetamine responses in SELENOP1 KO slices (66.8 ± 5.3%; n = 3; ****p < 0.0001). Values shown here for WT and SELENOP1 KO groups without quinpirole are the same data previously shown in Figure 3C. All values reported are mean ± SEM.